Compare SUPN & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | MTRN |
|---|---|---|
| Founded | 2005 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2010 | 2000 |
| Metric | SUPN | MTRN |
|---|---|---|
| Price | $55.61 | $160.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $61.60 | ★ $69.75 |
| AVG Volume (30 Days) | ★ 740.4K | 195.8K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.35% |
| EPS Growth | N/A | ★ 1178.57 |
| EPS | N/A | ★ 3.58 |
| Revenue | ★ $392,755,000.00 | N/A |
| Revenue This Year | $23.19 | $15.31 |
| Revenue Next Year | $17.65 | $7.57 |
| P/E Ratio | ★ N/A | $44.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.16 | $69.10 |
| 52 Week High | $59.68 | $172.03 |
| Indicator | SUPN | MTRN |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 59.53 |
| Support Level | $47.95 | $113.78 |
| Resistance Level | $58.67 | $172.03 |
| Average True Range (ATR) | 2.26 | 7.92 |
| MACD | 0.38 | 0.32 |
| Stochastic Oscillator | 60.13 | 60.10 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.